NKGen Biotech, Inc. Warrants
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refracto… Read more
NKGen Biotech, Inc. Warrants (NKGNW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.086x
Based on the latest financial reports, NKGen Biotech, Inc. Warrants (NKGNW) has a cash flow conversion efficiency ratio of 0.086x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.00 Million) by net assets ($-69.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NKGen Biotech, Inc. Warrants - Cash Flow Conversion Efficiency Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NKGen Biotech, Inc. Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NKGen Biotech, Inc. Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DELPHI AUTOMOTIVE
BE:D7A
|
0.054x |
|
THE BITCOIN FUND UTS A
F:7T9
|
N/A |
|
Thor Mining PLC
PINK:THORF
|
0.000x |
|
Multi Retail Group Ltd
TA:MRG
|
0.584x |
|
Jade Leader Corp
PINK:MCKRF
|
-0.018x |
|
REALTY
MU:RY6
|
0.025x |
|
ACME Lithium Inc
OTCQB:ACLHF
|
-0.006x |
|
AXIS SP GDR REG-S (UZC.SG)
STU:UZC
|
N/A |
Annual Cash Flow Conversion Efficiency for NKGen Biotech, Inc. Warrants (2021–2023)
The table below shows the annual cash flow conversion efficiency of NKGen Biotech, Inc. Warrants from 2021 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-58.69 Million | $-21.95 Million | 0.374x | +102.59% |
| 2022-12-31 | $1.56 Million | $-22.56 Million | -14.432x | -2909.30% |
| 2021-12-31 | $-38.05 Million | $-19.55 Million | 0.514x | -- |